Home
LRMR
LRMR News

Latest Larimar Therapeutics Inc. (LRMR) News on December 18, 2024

Larimar Therapeutics announces initial data from OLE study of nomlabofusp

TipRanks

a day ago

Larimar Therapeutics announces initial data from OLE study of nomlabofusp

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

GlobeNewswire

2 days ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

GlobeNewswire

a month ago

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

GlobeNewswire

2 months ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Simply Wall St.

2 months ago

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

GlobeNewswire

3 months ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Larimar Therapeutics to Participate in Upcoming Investor Conferences

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

GlobeNewswire

4 months ago

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock

Simply Wall St.

5 months ago

Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

GlobeNewswire

7 months ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

GlobeNewswire

7 months ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Simply Wall St.

7 months ago

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

GlobeNewswire

7 months ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

GuruFocus.com

9 months ago

Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

GlobeNewswire

9 months ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

GlobeNewswire

9 months ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire

9 months ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

10 months ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

GlobeNewswire

10 months ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Larimar Therapeutics Announces Proposed Underwritten Public Offering

GlobeNewswire

10 months ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

GlobeNewswire

10 months ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

Thomson Reuters StreetEvents

a year ago

Q3 2024 8x8 Inc Earnings Call

8x8 (EGHT) Q3 Earnings Surpass Estimates

Zacks

a year ago

8x8 (EGHT) Q3 Earnings Surpass Estimates

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

Business Wire

a year ago

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

Associated Press Finance

a year ago

Northrim: Q4 Earnings Snapshot

Northrim BanCorp Earns $6.6 million, or $1.19 Per Diluted Share, in Fourth Quarter 2023, and $25.4 Million, or $4.49 Per Diluted Share, for the Year Ended December 31, 2023

GlobeNewswire

a year ago

Northrim BanCorp Earns $6.6 million, or $1.19 Per Diluted Share, in Fourth Quarter 2023, and $25.4 Million, or $4.49 Per Diluted Share, for the Year Ended December 31, 2023

Pure Cycle First Quarter 2024 Earnings: EPS: US$0.086 (vs US$0.007 in 1Q 2023)

Simply Wall St.

a year ago

Pure Cycle First Quarter 2024 Earnings: EPS: US$0.086 (vs US$0.007 in 1Q 2023)

Canopy Growth Announces Upsized US$35 Million Private Placement

PR Newswire

a year ago

Canopy Growth Announces Upsized US$35 Million Private Placement

SunCoke Energy, Inc. Announces Fourth Quarter 2023 Earnings Date

Business Wire

a year ago

SunCoke Energy, Inc. Announces Fourth Quarter 2023 Earnings Date

Transphorm Announces Two 4-Lead TO-247 Devices, Expanding Product Portfolio for High Power Server, Renewable, Industrial Power Conversion

Business Wire

a year ago

Transphorm Announces Two 4-Lead TO-247 Devices, Expanding Product Portfolio for High Power Server, Renewable, Industrial Power Conversion

Q3 Traditional Fast Food Earnings: Arcos Dorados (NYSE:ARCO) Impresses

StockStory

a year ago

Q3 Traditional Fast Food Earnings: Arcos Dorados (NYSE:ARCO) Impresses

Zacks Industry Outlook Highlights Oil States International, Matrix Service and Profire Energy

Zacks

a year ago

Zacks Industry Outlook Highlights Oil States International, Matrix Service and Profire Energy

1 Growth Stock Down 96% You'll Regret Not Buying on the Dip in 2024

Motley Fool

a year ago

1 Growth Stock Down 96% You'll Regret Not Buying on the Dip in 2024

Millionaire-Makers: 3 Soaring Stocks to Transform Your Portfolio by 2026

InvestorPlace

a year ago

Millionaire-Makers: 3 Soaring Stocks to Transform Your Portfolio by 2026

3 Overlooked Stocks to Triple Your Investment by 2025

InvestorPlace

a year ago

3 Overlooked Stocks to Triple Your Investment by 2025

With 50% ownership of the shares, Angel Oak Mortgage REIT, Inc. (NYSE:AOMR) is heavily dominated by institutional owners

Simply Wall St.

a year ago

With 50% ownership of the shares, Angel Oak Mortgage REIT, Inc. (NYSE:AOMR) is heavily dominated by institutional owners

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

GlobeNewswire

a year ago

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Co-Founder of Cibus Picks Up 23% More Stock

Simply Wall St.

a year ago

Co-Founder of Cibus Picks Up 23% More Stock

Norwood Financial Corp Increases Cash Dividend

GlobeNewswire

a year ago

Norwood Financial Corp Increases Cash Dividend

Strength Seen in First Financial Corp. (THFF): Can Its 5.7% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in First Financial Corp. (THFF): Can Its 5.7% Jump Turn into More Strength?

JPMorgan names Amazon, Google as 'top picks' for 2024 stocks

Yahoo Finance

a year ago

JPMorgan names Amazon, Google as 'top picks' for 2024 stocks

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

GlobeNewswire

a year ago

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors

Simply Wall St.

a year ago

With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors

Should Value Investors Buy Civeo (CVEO) Stock?

Zacks

a year ago

Should Value Investors Buy Civeo (CVEO) Stock?

Pleasing Signs As A Number Of Insiders Buy Shyft Group Stock

Simply Wall St.

a year ago

Pleasing Signs As A Number Of Insiders Buy Shyft Group Stock

Agora, Inc. Announces Executive Leadership Update

GlobeNewswire

a year ago

Agora, Inc. Announces Executive Leadership Update

Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?

Zacks

a year ago

Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?

Global Indemnity Group, LLC Suspends the Exploration of the Sale or Merger of Penn-America and Global Indemnity

Business Wire

a year ago

Global Indemnity Group, LLC Suspends the Exploration of the Sale or Merger of Penn-America and Global Indemnity

PureCycle Resumes Pellet Production at Ironton Purification Facility

ACCESSWIRE

a year ago

PureCycle Resumes Pellet Production at Ironton Purification Facility

The Zacks Analyst Blog Highlights DoubleDown, Grand Canyon Education, Royal Caribbean Cruises, Live Nation Entertainment and Comcast

Zacks

a year ago

The Zacks Analyst Blog Highlights DoubleDown, Grand Canyon Education, Royal Caribbean Cruises, Live Nation Entertainment and Comcast

Semler Scientific, Inc.'s (NASDAQ:SMLR) high institutional ownership speaks for itself as stock continues to impress, up 22% over last week

Simply Wall St.

a year ago

Semler Scientific, Inc.'s (NASDAQ:SMLR) high institutional ownership speaks for itself as stock continues to impress, up 22% over last week

Is Armada Hoffler Properties, Inc.'s (NYSE:AHH) 5.0% ROE Better Than Average?

Simply Wall St.

a year ago

Is Armada Hoffler Properties, Inc.'s (NYSE:AHH) 5.0% ROE Better Than Average?

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire

a year ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Tejon Ranch (NYSE:TRC) shareholders have endured a 13% loss from investing in the stock five years ago

Simply Wall St.

a year ago

Tejon Ranch (NYSE:TRC) shareholders have endured a 13% loss from investing in the stock five years ago

Thomson Reuters StreetEvents

a year ago

Q3 2023 United Fire Group Inc Earnings Call

Share on Social Networks: